ATXS — Astria Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $738.11m
- $605.71m
Annual cashflow statement for Astria Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -37.3 | -195 | -51.8 | -72.9 | -94.3 |
| Non-Cash Items | 1.45 | 168 | 5.65 | 6.86 | 8.51 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.37 | -3.31 | 2.65 | -2.41 | 4.54 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -32.5 | -30.2 | -43.5 | -68.4 | -81.2 |
| Capital Expenditures | -0.033 | -0.021 | -0.091 | -0.025 | -0.325 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 6.33 | -12.5 | -167 | 135 | -192 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 6.3 | -12.6 | -167 | 135 | -192 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 40.9 | 104 | 145 | 88.4 | 157 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.7 | 61.6 | -65.9 | 155 | -116 |